Charles River Laboratories (CRL) - Net Assets
Based on the latest financial reports, Charles River Laboratories (CRL) has net assets worth $2.99 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.73 Billion) and total liabilities ($4.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CRL total asset value for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.99 Billion |
| % of Total Assets | 38.66% |
| Annual Growth Rate | 11.53% |
| 5-Year Change | 23.89% |
| 10-Year Change | 276.11% |
| Growth Volatility | 60.76 |
Charles River Laboratories - Net Assets Trend (1998–2025)
This chart illustrates how Charles River Laboratories's net assets have evolved over time, based on quarterly financial data. Check CRL tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Charles River Laboratories (1998–2025)
The table below shows the annual net assets of Charles River Laboratories from 1998 to 2025. For live valuation and market cap data, see CRL market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.21 Billion | -8.46% |
| 2024-12-31 | $3.51 Billion | -4.12% |
| 2023-12-31 | $3.66 Billion | +21.02% |
| 2022-12-31 | $3.02 Billion | +16.65% |
| 2021-12-31 | $2.59 Billion | +20.91% |
| 2020-12-31 | $2.14 Billion | +28.63% |
| 2019-12-31 | $1.67 Billion | +24.52% |
| 2018-12-31 | $1.34 Billion | +25.78% |
| 2017-12-31 | $1.06 Billion | +24.62% |
| 2016-12-31 | $853.78 Million | +11.52% |
| 2015-12-31 | $765.56 Million | +8.69% |
| 2014-12-31 | $704.35 Million | +5.97% |
| 2013-12-31 | $664.66 Million | +10.19% |
| 2012-12-31 | $603.20 Million | +14.00% |
| 2011-12-31 | $529.14 Million | -23.17% |
| 2010-12-31 | $688.73 Million | -49.87% |
| 2009-12-31 | $1.37 Billion | +14.54% |
| 2008-12-31 | $1.20 Billion | -35.65% |
| 2007-12-31 | $1.86 Billion | +16.18% |
| 2006-12-31 | $1.60 Billion | -12.65% |
| 2005-12-31 | $1.84 Billion | +23.91% |
| 2004-12-31 | $1.48 Billion | +212.19% |
| 2003-12-31 | $474.80 Million | +26.30% |
| 2002-12-31 | $375.94 Million | +24.28% |
| 2001-12-31 | $302.50 Million | +132.23% |
| 2000-12-31 | $130.26 Million | +218.59% |
| 1999-12-31 | $-109.84 Million | -165.16% |
| 1998-12-31 | $168.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Charles River Laboratories's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 789.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.39 Billion | 43.88% |
| Common Stock | $492.00K | 0.02% |
| Other Comprehensive Income | $-171.78 Million | -5.43% |
| Other Components | $1.95 Billion | 61.53% |
| Total Equity | $3.16 Billion | 100.00% |
Charles River Laboratories Competitors by Market Cap
The table below lists competitors of Charles River Laboratories ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenyang Fortune Precision Equipment Co. Ltd. A
SHG:688409
|
$9.15 Billion |
|
Petro Rio S.A.
SA:PRIO3
|
$9.15 Billion |
|
Vanguard International Semiconductor
TWO:5347
|
$9.15 Billion |
|
TORAY INDUSTRIES ADR/2
F:6HK
|
$9.16 Billion |
|
Bentley Systems Inc
NASDAQ:BSY
|
$9.14 Billion |
|
China Merchants Shekou Industrial Zone Holdings
SHE:001979
|
$9.13 Billion |
|
ALSTOM S.A. UNSP.ADR 1/10
F:AOMU
|
$9.13 Billion |
|
Novatek Microelectronics Corp
TW:3034
|
$9.13 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Charles River Laboratories's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,461,503,000 to 3,164,630,000, a change of -296,873,000 (-8.6%).
- Net loss of 144,338,000 reduced equity.
- Share repurchases of 360,673,000 reduced equity.
- Other comprehensive income increased equity by 145,562,000.
- Other factors increased equity by 62,576,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-144.34 Million | -4.56% |
| Share Repurchases | $360.67 Million | -11.4% |
| Other Comprehensive Income | $145.56 Million | +4.6% |
| Other Changes | $62.58 Million | +1.98% |
| Total Change | $- | -8.58% |
Book Value vs Market Value Analysis
This analysis compares Charles River Laboratories's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.44x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.41x to 3.44x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $16.36 | $219.40 | x |
| 1999-12-31 | $-5.56 | $219.40 | x |
| 2000-12-31 | $3.65 | $219.40 | x |
| 2001-12-31 | $6.54 | $219.40 | x |
| 2002-12-31 | $7.56 | $219.40 | x |
| 2003-12-31 | $9.51 | $219.40 | x |
| 2004-12-31 | $26.27 | $219.40 | x |
| 2005-12-31 | $25.22 | $219.40 | x |
| 2006-12-31 | $22.88 | $219.40 | x |
| 2007-12-31 | $27.07 | $219.40 | x |
| 2008-12-31 | $17.82 | $219.40 | x |
| 2009-12-31 | $20.93 | $219.40 | x |
| 2010-12-31 | $10.99 | $219.40 | x |
| 2011-12-31 | $10.28 | $219.40 | x |
| 2012-12-31 | $12.41 | $219.40 | x |
| 2013-12-31 | $13.22 | $219.40 | x |
| 2014-12-31 | $14.13 | $219.40 | x |
| 2015-12-31 | $15.39 | $219.40 | x |
| 2016-12-31 | $17.45 | $219.40 | x |
| 2017-12-31 | $21.52 | $219.40 | x |
| 2018-12-31 | $26.87 | $219.40 | x |
| 2019-12-31 | $32.89 | $219.40 | x |
| 2020-12-31 | $41.78 | $219.40 | x |
| 2021-12-31 | $49.29 | $219.40 | x |
| 2022-12-31 | $58.02 | $219.40 | x |
| 2023-12-31 | $69.91 | $219.40 | x |
| 2024-12-31 | $67.05 | $219.40 | x |
| 2025-12-31 | $63.85 | $219.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Charles River Laboratories utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3.59%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 2.25x
- Recent ROE (-4.56%) is below the historical average (6.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 13.89% | 12.09% | 0.83x | 1.39x | $6.55 Million |
| 1999 | 0.00% | 7.81% | 0.60x | 0.00x | $28.14 Million |
| 2000 | -9.60% | -3.66% | 0.75x | 3.51x | $-22.92 Million |
| 2001 | 12.23% | 7.60% | 0.81x | 1.97x | $6.46 Million |
| 2002 | 14.03% | 9.04% | 0.79x | 1.96x | $14.39 Million |
| 2003 | 17.25% | 13.06% | 0.77x | 1.72x | $33.69 Million |
| 2004 | 6.10% | 11.71% | 0.29x | 1.78x | $-57.46 Million |
| 2005 | 7.77% | 12.65% | 0.44x | 1.39x | $-40.70 Million |
| 2006 | -3.50% | -5.27% | 0.41x | 1.60x | $-215.30 Million |
| 2007 | 8.30% | 12.55% | 0.44x | 1.51x | $-31.64 Million |
| 2008 | -43.52% | -38.84% | 0.62x | 1.80x | $-641.75 Million |
| 2009 | 8.33% | 9.52% | 0.55x | 1.60x | $-22.94 Million |
| 2010 | -48.98% | -29.70% | 0.65x | 2.52x | $-405.41 Million |
| 2011 | 20.78% | 9.59% | 0.73x | 2.95x | $56.83 Million |
| 2012 | 16.19% | 8.61% | 0.71x | 2.64x | $37.21 Million |
| 2013 | 16.04% | 8.82% | 0.71x | 2.57x | $38.73 Million |
| 2014 | 18.85% | 9.76% | 0.69x | 2.80x | $59.48 Million |
| 2015 | 20.37% | 10.95% | 0.66x | 2.82x | $76.01 Million |
| 2016 | 18.50% | 9.20% | 0.62x | 3.24x | $71.09 Million |
| 2017 | 11.80% | 6.64% | 0.63x | 2.80x | $18.85 Million |
| 2018 | 17.18% | 9.99% | 0.59x | 2.93x | $94.64 Million |
| 2019 | 15.42% | 9.61% | 0.56x | 2.87x | $88.56 Million |
| 2020 | 17.23% | 12.46% | 0.53x | 2.60x | $152.84 Million |
| 2021 | 15.42% | 11.04% | 0.50x | 2.77x | $137.50 Million |
| 2022 | 16.34% | 12.23% | 0.52x | 2.55x | $188.60 Million |
| 2023 | 13.20% | 11.49% | 0.50x | 2.28x | $114.94 Million |
| 2024 | 0.30% | 0.25% | 0.54x | 2.17x | $-335.85 Million |
| 2025 | -4.56% | -3.59% | 0.56x | 2.25x | $-460.80 Million |
Industry Comparison
This section compares Charles River Laboratories's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $312,558,365
- Average return on equity (ROE) among peers: -201.95%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Charles River Laboratories (CRL) | $2.99 Billion | 13.89% | 1.59x | $9.14 Billion |
| Agilent Technologies Inc (A) | $3.02 Billion | 8.50% | 0.65x | $37.61 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.66 Million | -167.28% | 1.68x | $8.80 Million |
| Applied DNA Sciences Inc (APDN) | $5.71 Million | -223.57% | 0.99x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $210.64 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $3.17 Million |
| Biocept Inc. (BIOCQ) | $23.69 Million | -75.16% | 1.00x | $262.60 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.57 Billion |
| Burning Rock Biotech Ltd (BNR) | $168.49 Million | -77.91% | 1.38x | $83.29 Million |
| CareDx Inc (CDNA) | $-150.67 Million | 0.00% | 0.00x | $1.42 Billion |
| Check Cap Ltd (CHEK) | $23.69 Million | -74.17% | 0.06x | $9.42 Million |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more